ABSTRACT We investigated the prognostic impact of minimal residual disease (MRD) monitoring in acute myeloid leukemia patients harboring _DNA methyltransferase 3A-_R882H/-R882C mutations

(_DNMT3A_mut). MRD was determined by real-time quantitative PCR (RQ-PCR) in 1494 samples of 181 _DNMT3A_mut patients. At the time of diagnosis, _DNMT3A_mut transcript levels did not

correlate with presenting clinical characteristics and concurrent gene mutations as well as the survival end points. In Cox regression analyses, bone marrow (BM) _DNMT3A_mut transcript

levels (log10-transformed continuous variable) were not associated with the rate of relapse or death. _DNMT3A_mut transcript levels were significantly higher in BM than in blood after

RQ-PCR negativity, whereas most had constantly high _DNMT3A_mut transcript levels, a finding which is consistent with the persistence of clonal hematopoiesis in hematological remission.

Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this

journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now

Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer

support SIMILAR CONTENT BEING VIEWED BY OTHERS GENOMIC AND TRANSCRIPTOMIC DETERMINANTS OF CLINICAL OUTCOMES IN PATIENTS WITH AML AND _DNMT3A_ MUTATIONS Article Open access 20 May 2025

MULTI-TARGET MEASURABLE RESIDUAL DISEASE ASSESSED BY ERROR-CORRECTED SEQUENCING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: AN ALFA STUDY Article Open access 13 June 2024 _ASXL1_ MUTATIONS

PREDICT INFERIOR MOLECULAR RESPONSE TO NILOTINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA Article Open access 28 July 2022 REFERENCES * Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR,

Büchner T _et al_. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. _Blood_ 2017; 129: 424–447. Article  Google Scholar  * Döhner H,

Weisdorf DJ, Bloomfield CD . Acute myeloid leukemia. _N Engl J Med_ 2015; 373: 1136–1152. Article  Google Scholar  * Grimwade D, Freeman SD . Defining minimal residual disease in acute

myeloid leukemia: which platforms are ready for ‘prime time’? _Hematology Am Soc Hematol Educ Program_ 2014; 2014: 222–233. Article  Google Scholar  * Bullinger L, Döhner K, Döhner H .

Genomics of acute myeloid leukemia diagnosis and pathways. _J Clin Oncol_ 2017; 35: 934–946. Article  CAS  Google Scholar  * Inaba H, Coustan-Smith E, Cao X, Pounds SB, Shurtleff SA, Wang KY

_et al_. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. _J Clin Oncol_ 2012; 30: 3625–3632. Article  Google Scholar  * Haferlach T,

Meggendorfer M, Schnittger S, Fasan A, Kern W, Haferlach C . Clinical impact of minimal residual disease (MRD) monitoring in AML with PML-Rara, CBFB-MYH11, and RUNX1-RUNX1T1: a study on 600

patients. _Blood_ 2015; 126: (abstract 228). * Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH _et al_. Management of acute promyelocytic leukemia: recommendations from an

expert panel on behalf of the European LeukemiaNet. _Blood_ 2009; 113: 1875–1891. Article  CAS  Google Scholar  * Corbacioglu A, Scholl C, Schlenk RF, Eiwen K, Du J, Bullinger L _et al_.

Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. _J Clin Oncol_ 2010; 28: 3724–3729. Article  CAS  Google Scholar  * Yin JA, O'Brien MA,

Hills RK, Daly SB, Wheatley K, Burnett AK . Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of

the United Kingdom MRC AML-15 trial. _Blood_ 2012; 120: 2826–2835. Article  CAS  Google Scholar  * Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P _et al_.

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. _Blood_ 2013; 121: 2213–2223. Article  CAS  Google Scholar

  * Krönke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI _et al_. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the

German-Austrian acute myeloid leukemia study group. _J Clin Oncol_ 2011; 29: 2709–2716. Article  Google Scholar  * Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B _et al_.

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. _Blood_ 2009; 114: 2220–2231. Article  CAS  Google Scholar  * Ivey

A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A _et al_. Assessment of minimal residual disease in standard-risk AML. _N Engl J Med_ 2016; 374: 422–433. Article  CAS  Google Scholar

  * Krönke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik VI, Kühn MW _et al_. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. _Blood_ 2013; 122: 100–108. Article  Google

Scholar  * Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A _et al_. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of

the AML Study Group (AMLSG). _Blood_ 2013; 121: 4769–4777. Article  CAS  Google Scholar  * Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE _et al_. DNMT3A mutations in acute

myeloid leukemia. _N Engl J Med_ 2010; 363: 2424–2433. Article  CAS  Google Scholar  * Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M _et al_. Incidence and prognostic influence

of DNMT3A mutations in acute myeloid leukemia. _J Clin Oncol_ 2011; 29: 2889–2896. Article  CAS  Google Scholar  * Marková J, Michková P, Burčková K, Březinová J, Michalová K, Dohnalová A

_et al_. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. _Eur J Haematol_ 2011; 88: 128–135. Article  Google Scholar  *

LaRochelle O, Bertoli S, Vergez F, Sarry JE, Mansat-De Mas V, Dobbelstein S _et al_. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A

single center experience. _Oncotarget_ 2011; 2: 850–861. Article  Google Scholar  * Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C _et al_. Prognostic significance of

DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. _Leukemia_ 2012; 26: 1247–1254. Article  CAS  Google

Scholar  * Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY _et al_. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. _Blood_ 2011;

119: 559–568. Article  Google Scholar  * Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, Rockova V, Sanders M, Abbas S _et al_. Mutant DNMT3A: a marker of poor prognosis in acute myeloid

leukemia. _Blood_ 2012; 119: 5824–5831. Article  CAS  Google Scholar  * Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrózek K _et al_. Age-related prognostic impact of different

types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. _J Clin Oncol_ 2012; 30: 742–750. Article  Google Scholar  * Ostronoff F, Othus M, Ho PA,

Kutny M, Geraghty DE, Petersdorf SH _et al_. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. _Leukemia_ 2013;

27: 238–241. Article  CAS  Google Scholar  * Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R . Preleukemic mutations in human acute myeloid leukemia affect epigenetic

regulators and persist in remission. _Proc Natl Acad Sci USA_ 2014; 111: 2548–2553. Article  CAS  Google Scholar  * Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR _et

al_. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. _Sci Transl Med_ 2012; 4: 149ra118. Article  Google Scholar  * Welch JS, Ley TJ, Link DC,

Miller CA, Larson DE, Koboldt DC _et al_. The origin and evolution of mutations in acute myeloid leukemia. _Cell_ 2012; 150: 264–278. Article  CAS  Google Scholar  * Ding L, Ley TJ, Larson

DE, Miller CA, Koboldt DC, Welch JS _et al_. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. _Nature_ 2012; 481: 506–510. Article  CAS  Google

Scholar  * Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V _et al_. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. _Nature_ 2014; 506: 328–333.

Article  CAS  Google Scholar  * Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC _et al_. Age-related mutations associated with clonal hematopoietic expansion and malignancies. _Nat

Med_ 2014; 20: 1472–1478. Article  CAS  Google Scholar  * Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF _et al_. Clonal hematopoiesis and blood-cancer risk inferred

from blood DNA sequence. _N Engl J Med_ 2014; 371: 2477–2487. Article  Google Scholar  * Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG _et al_. Age-related clonal

hematopoiesis associated with adverse outcomes. _N Engl J Med_ 2014; 371: 2488–2498. Article  Google Scholar  * Schlenk RF, Döhner K, Mack S, Stoppel M, Király F, Götze K _et al_.

Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia:

German-Austrian trial AMLHD98A. _J Clin Oncol_ 2010; 28: 4642–4648. Article  Google Scholar  * Schlenk RF, Lübbert M, Benner A, Lamparter A, Krauter J, Herr W _et al_. All-trans retinoic

acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. _Ann Hematol_ 2016; 95: 1931–1942. Article  CAS 

Google Scholar  * Simons A, Shaffer LG, Hastings RJ . Cytogenetic nomenclature: changes in the ISCN 2013 compared to the 2009 edition. _Cytogenet Genome Res_ 2013; 141: 1–6. Article  CAS 

Google Scholar  * Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L _et al_. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. _N Engl J

Med_ 2008; 358: 1909–1918. Article  CAS  Google Scholar  * Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E _et al_. Evaluation of candidate control genes for

diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer

program. _Leukemia_ 2003; 17: 2474–2486. Article  CAS  Google Scholar  * Korn EL . Censoring distributions as a measure of follow-up in survival analysis. _Stat Med_ 1986; 5: 255–260.

Article  CAS  Google Scholar  * Kaplan E, Meier P . Nonparametric estimation from incomplete observations. _J Am Stat Assoc_ 1958; 53: 457–481. Article  Google Scholar  * Therneau TM,

Grambusch PM . _Modeling Survival Data: Extending the Cox Model_. Springer Verlag: New York, NY, USA, 2000. Book  Google Scholar  * Cox DR . Regression models and life tables (with

discussion). _J R Stat Soc B_ 1972; 34: 187–220. Google Scholar  * Harrell FE . _Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival

Analysis_. Springer Verlag: New York, NY, USA, 2001. Book  Google Scholar  * R Development Core Team _R: A Language and Environment for Statistical Computing_. R Foundation for Statistical

Computing: Vienna, Austria, 2009. * Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O _et al_. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual

disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. _Oncotarget_ 2015; 6: 42345–42353. Article  Google Scholar  * Jeziskova I, Musilova

M, Culen M, Foltankova V, Dvorakova D, Mayer J _et al_. Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML. _Int

J Hematol_ 2015; 102: 553–557. Article  CAS  Google Scholar  * Pløen GG, Nederby L, Guldberg P, Hansen M, Ebbesen LH, Jensen UB _et al_. Persistence of DNMT3A mutations at long-term

remission in adult patients with AML. _Br J Haematol_ 2014; 167: 478–486. Article  Google Scholar  * Bhatnagar B, Eisfeld AK, Nicolet D, Mrózek K, Blachly JS, Orwick S _et al_. Persistence

of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. _Br J Haematol_ 2016; 175: 226–236. Article  CAS  Google Scholar  *

Brambati C, Galbiati S, Xue E, Toffalori C, Crucitti L, Greco R _et al_. Droplet digital PCR for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse

after allogeneic hematopoietic stem cell transplantation. _Haematologica_ 2016; 101: e157–e161. Article  CAS  Google Scholar  * Berenstein R, Blau IW, Suckert N, Baldus C, Pezzutto A, Dörken

B _et al_. Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia. _J Exp Clin Cancer Res_ 2015; 34: 55. Article  Google Scholar  * Göhring G, Thomay K, Schmidt G,

Ripperger T, Xu M, Wittner N _et al_. A common ancestral DNMT3A-mutated preleukemic clone giving rise to AML and MDS in an adolescent girl. _Leuk Lymphoma_ 2017; 58: 718–721. Article  Google

Scholar  * Thol F, Klesse S, Köhler L, Gabdoulline R, Kloos A, Liebich A _et al_. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. _Leukemia_ 2017; 31: 1286–1295.

Article  CAS  Google Scholar  * Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND _et al_. Genomic classification and prognosis in acute myeloid leukemia. _N Engl J

Med_ 2016; 374: 2209–2221. Article  CAS  Google Scholar  Download references ACKNOWLEDGEMENTS This work was supported in part by grants 01GI9981 and 01KG0605 from the German

Bundesministerium für Bildung und Forschung (BMBF), grant 109675 from the Deutsche Krebshilfe and the Sonderforschungsbereich (SFB) 1074 funded by the Deutsche Forschungsgemeinschaft (SFB

1074, projects B3 and B4). VG is a grant recipient of the Else-Kröner-Forschungskolleg; LB and MH are Heisenberg Professors of the Deutsche Forschungsgemeinschaft (DFG, BU 1339/3-1 and HE

5240-6-1). AMLSG treatment trials were in part supported by Pfizer and Amgen. We are grateful to all members of the German-Austrian AML Study Group (AMLSG) for their participation in this

study and providing patient samples; a list of participating institutions and investigators is provided in the Supplementary Appendix. AUTHOR CONTRIBUTIONS VIG, DW, RFS, KD and HD designed

the research; VIG, PP, AK, SK, AC, JK and SKS performed experiments; VIG, VT, PP, AK, SK, AC, JK, SKS and KD analyzed the results; DW and RFS performed statistical analyses; DK, HAH, ISW,

GH, AK, MR, KG, TK, WF, MW, LB, VT, BS, FT, MH, AG, RFS, HD and KD accrued patients and provided material; VIG, DW, HD and KD wrote the paper. AUTHOR INFORMATION Author notes * A complete

list of the members of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG) is provided in Supplementary Information. AUTHORS AND AFFILIATIONS * Universitätsklinikum Ulm, Ulm,

Germany V I Gaidzik, D Weber, P Paschka, A Kaumanns, S Krieger, A Corbacioglu, J Krönke, S Kapp-Schwoerer, R F Schlenk, L Bullinger, V Teleanu, H Döhner & K Döhner * Klinikum Oldenburg,

Oldenburg, Germany D Krämer * Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany H-A Horst * Universitätsklinikum Bonn, Bonn, Germany I Schmidt-Wolf * Universitätsklinikum

des Saarlandes, Homburg, Germany G Held * Universitätsklinikum Düsseldorf, Düsseldorf, Germany A Kündgen * Städtisches Klinikum Karlsruhe GmbH, Karlsruhe, Germany M Ringhoffer * Klinikum

rechts der Isar der Technischen Universität München, München, Germany K Götze * Universitätsmedizin Mainz, Mainz, Germany T Kindler * Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

W Fiedler * Kliniken Essen Süd, Ev. Krankenhaus Essen-Werden gGmbH, Essen, Germany M Wattad * Medizinische Hochschule Hannover, Hannover, Germany B Schlegelberger, F Thol, M Heuser & A

Ganser Authors * V I Gaidzik View author publications You can also search for this author inPubMed Google Scholar * D Weber View author publications You can also search for this author

inPubMed Google Scholar * P Paschka View author publications You can also search for this author inPubMed Google Scholar * A Kaumanns View author publications You can also search for this

author inPubMed Google Scholar * S Krieger View author publications You can also search for this author inPubMed Google Scholar * A Corbacioglu View author publications You can also search

for this author inPubMed Google Scholar * J Krönke View author publications You can also search for this author inPubMed Google Scholar * S Kapp-Schwoerer View author publications You can

also search for this author inPubMed Google Scholar * D Krämer View author publications You can also search for this author inPubMed Google Scholar * H-A Horst View author publications You

can also search for this author inPubMed Google Scholar * I Schmidt-Wolf View author publications You can also search for this author inPubMed Google Scholar * G Held View author

publications You can also search for this author inPubMed Google Scholar * A Kündgen View author publications You can also search for this author inPubMed Google Scholar * M Ringhoffer View

author publications You can also search for this author inPubMed Google Scholar * K Götze View author publications You can also search for this author inPubMed Google Scholar * T Kindler

View author publications You can also search for this author inPubMed Google Scholar * W Fiedler View author publications You can also search for this author inPubMed Google Scholar * M

Wattad View author publications You can also search for this author inPubMed Google Scholar * R F Schlenk View author publications You can also search for this author inPubMed Google Scholar

* L Bullinger View author publications You can also search for this author inPubMed Google Scholar * V Teleanu View author publications You can also search for this author inPubMed Google

Scholar * B Schlegelberger View author publications You can also search for this author inPubMed Google Scholar * F Thol View author publications You can also search for this author inPubMed

 Google Scholar * M Heuser View author publications You can also search for this author inPubMed Google Scholar * A Ganser View author publications You can also search for this author

inPubMed Google Scholar * H Döhner View author publications You can also search for this author inPubMed Google Scholar * K Döhner View author publications You can also search for this

author inPubMed Google Scholar CONSORTIA FOR THE GERMAN-AUSTRIAN ACUTE MYELOID LEUKEMIA STUDY GROUP (AMLSG) CORRESPONDING AUTHOR Correspondence to K Döhner. ETHICS DECLARATIONS COMPETING

INTERESTS The authors declare no conflict of interest. ADDITIONAL INFORMATION Presented in abstract form at the 57th Annual Meeting of the American Society of Hematology, Orlando, FL, USA on

6 December 2015. Supplementary Information accompanies this paper on the Leukemia website SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION (DOCX 1127 KB) RIGHTS AND PERMISSIONS Reprints

and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Gaidzik, V., Weber, D., Paschka, P. _et al._ _DNMT3A_ mutant transcript levels persist in remission and do not predict outcome in

patients with acute myeloid leukemia. _Leukemia_ 32, 30–37 (2018). https://doi.org/10.1038/leu.2017.200 Download citation * Received: 08 June 2017 * Accepted: 13 June 2017 * Published: 23

June 2017 * Issue Date: January 2018 * DOI: https://doi.org/10.1038/leu.2017.200 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable

link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative